AR and metastatic prostate carcinoma: Collectively, these findings demonstrate that inhibition of neutrophilic ROS induces death of AR-negative (PC3, PAIII), with little impact on AR-positive (C42B, RM1), castration-resistant metastatic prostate cancer.